Clicky

Aurinia Pharmaceuticals Inc(AUPH)

Description: Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.


Keywords: Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Disease Clinical Development Peptides Immunosuppressants Nephrology Lupus Lupus Nephritis Vifor Pharma Nephritis

Home Page: www.auriniapharma.com

AUPH Technical Analysis

4464 Markham Street
Victoria, BC V8Z 7X8
Canada
Phone: 250 744 2487


Officers

Name Title
Mr. Peter S. Greenleaf M.B.A. Pres, CEO & Director
Mr. Joseph M. Miller CPA Chief Financial Officer
Mr. Matthew Maxwell Donley M.B.A. Exec. VP of Operations & Strategy
Mr. Stephen P. Robertson Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
Ms. DeDe Sheel VP of Investor Relation
Mr. Chris Hays VP of Marketing
Mr. Fran Lynch VP of Sales
Mr. Michael R. Martin Chief Bus. Officer
Ms. Sue Evans Head of Regulatory Affairs
Mr. Scott Habig Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 434.7826
Trailing PE: 0
Price-to-Book MRQ: 1.5673
Price-to-Sales TTM: 4.9298
IPO Date: 1999-01-26
Fiscal Year End: December
Full Time Employees: 300
Back to stocks